Phase 1 study of INCB086550, an oral PD-l1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors
Name:
Van Cutsem.pdf
Size:
973.4Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Van Cutsem, E.Prenen, H.
Delafontaine, B.
Spencer, K.
Mitchell, T.
Burris, H.
Kotecki, N.
Kristeleit, R.
Pinato, D.
Sahebjam, S.
Graham, Donna
Karasic, T.
Daniel, J.
O'Hayer, K.
Geschwindt, R.
Piha-Paul, S.
Affiliation
University of Leuven, Leuven, BelgiumIssue Date
2021
Metadata
Show full item recordAbstract
Background INCB086550 is an orally administered small molecule that binds PD-L1 and inhibits PD-1/PD-L1 interaction. Translational data demonstrating markers of immune activation in patients following INCB086550 were previously reported.1 Preliminary clinical data from this phase 1 study are presented below. Methods Adult patients (≥18 years) with advanced solid tumors were enrolled into this open-label study. Patients had disease progression after standard available therapy or were intolerant of or ineligible for standard treatment. Measurable disease was required. A modified 3+3 dose-escalation design was employed, followed by dose expansions. The primary endpoints were safety and tolerability of INCB086550, identification of a pharmacologically active dose and/or MTD, and confirmation of the RP2D. Secondary endpoints included PK, pharmacodynamics, and efficacy as assessed by investigator-determined ORR and DCR (CR, PR, or SD ≥12 weeks). Results As of 9Apr2021, 79 patients received treatment (Table 1); 57.0% were female, 62.0% had ≥2 prior lines of therapy, and 16% received prior IO treatment. Forty-six (58.2%) patients had treatment-related TEAEs; those occurring in ≥5% of patients are presented in Table 2. Ten patients (12.7%) had grade ≥3 treatment-related TEAEs. Immune-related TEAEs occurred in 15 patients (19.0%); the most common (>1 patient) included peripheral sensory neuropathy (n=5), pruritus (n=3), immune-mediated neuropathy (n=2), and peripheral motor neuropathy (n=2). In total, 10 (12.7%) patients had TEAEs of peripheral neuropathy; all were grade ≤3. All grade 2 or 3 TEAEs of peripheral neuropathy resolved or improved with either study drug continuation without dose modification, dose reduction, or drug interruption/discontinuation. Patients with TEAEs leading to treatment interruption were 21 (26.6%), dose reduction 5 (6.3%), and discontinuation 13 (16.5%). Five patients (6.3%) died of a TEAE (cerebrovascular accident, dyspnea, general physical health deterioration, intestinal obstruction, intracranial hemorrhage [each n=1]); all fatal TEAEs were considered unrelated to study drug. The efficacy-evaluable population included 68 patients; ORR was 11.8% (95%CI, 5.2%–21.9%; CR, 1.5%; PR, 10.3%), and DCR was 19.1% (95%CI, 10.6%–30.5%; Table 3). Eight objective responses were observed at doses ≥400 mg BID (Table 4); 3 of these were noted among the 5 IO treatment-naive patients with MSI-H tumors who received 400 mg BID. Conclusions Immune-related AEs observed in this ongoing phase 1 study are consistent with those seen with antibody immune checkpoint inhibitors, with the exception of peripheral neuropathy. Preliminary efficacy of INCB086550 in tumor types known to be responsive to anti-PD-(L)1 therapy is encouraging and warrants further investigation.Citation
Cutsem EV, Prenen H, Delafontaine B, Spencer K, Mitchell T, Burris H, et al. 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. Vol. 9, Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A559–60.Journal
Journal for Immunotherapy of CancerDOI
10.1136/jitc-2021-SITC2021.529Additional Links
https://dx.doi.org/10.1136/jitc-2021-SITC2021.529Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/jitc-2021-SITC2021.529